25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,313,000.

Other institutional investors also recently bought and sold shares of the company. OP Asset Management Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth about $422,000. Assenagon Asset Management S.A. bought a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $27,428,000. Campbell Newman Asset Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 1.7% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 44,808 shares of the specialty pharmaceutical company’s stock valued at $2,316,000 after acquiring an additional 738 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Supernus Pharmaceuticals by 2,847.0% in the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock valued at $19,498,000 after acquiring an additional 364,413 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its holdings in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $48.05 on Friday. The firm has a market capitalization of $2.79 billion, a P/E ratio of -94.22, a price-to-earnings-growth ratio of 1.03 and a beta of 0.54. Supernus Pharmaceuticals, Inc. has a 1 year low of $31.35 and a 1 year high of $59.68. The firm’s fifty day simple moving average is $47.18 and its 200 day simple moving average is $49.50.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SUPN. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.